FDA grants accelerated approval to YUVIWEL® (navepegritide), Ascendis Pharma’s once-weekly treatment the first for increasing linear growth in children aged 2+ with achondroplasia. Backed by pivotal trials, launches Q2 2026 with patient support.
Written By: Karthik Teja, PharmD
Reviewed By: Pharmacally Editorial Team
Ascendis Pharma A/S announced U.S. FDA accelerated approval of YUVIWEL® (navepegritide; TransCon® CNP), the first once-weekly treatment to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses.
Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma, expressed strong confidence in YUVIWEL’s transformative potential for achondroplasia treatment, thanking patients, clinicians, and advocates for their role in this milestone. The company highlights its focus on advocacy input to target community needs, reaffirming dedication to patient-important outcomes and new pharmacological possibilities.
Approval draws from three randomized, double-blind, placebo-controlled trials plus up to three years of open-label data, showing improved annualized growth velocity (AGV). Pivotal ApproaCH Trial (NCT05598320) results appear in JAMA Pediatrics; continued approval depends on confirmatory trials verifying clinical benefit.
Dr. Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, said the approval of once-weekly YUVIWEL represents a major advancement for treating children with achondroplasia, offering physicians their first once-weekly option supported by strong efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled trials. He emphasized his commitment to creating personalized care plans for children and parents, eagerly incorporating YUVIWEL into these discussions.
Availability and Support Programs
YUVIWEL launches via U.S. prescribers in early second quarter 2026 (Q2), backed by Ascendis Signature Access Program (A.S.A.P.) for navigation and financial aid. The FDA also granted a Rare Pediatric Disease Priority Review Voucher to spur rare disease innovation.
Community Voice
The Little People of America Board of Directors emphasized centering voices of people with dwarfism in research and treatment discussions like YUVIWEL, promoting dwarf and disability pride, inclusion, respect, and diverse dialogue. Their aim is to empower families in healthcare choices aligned with personal values while advocating for research and options that address community priorities.
Understanding Achondroplasia and Treatment Need
Achondroplasia, the most common form of dwarfism, stems from a genetic FGFR3 variant causing skeletal dysplasia and risks like muscular, neurological, and cardiorespiratory issues. YUVIWEL, a prodrug of C-type natriuretic peptide (CNP), counters overactive FGFR3 signaling by providing continuous CNP exposure across the weekly dosing interval.
Key Safety Note
YUVIWEL is for increasing linear growth in eligible children under accelerated approval. For complete U.S. prescribing information (PI), including adverse reactions (ADRs), warnings, and precautions, please consult prescribing information.
References
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older, 27 February 2026, https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children
Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children with Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatr. 2026;180(1):18–25. https://doi.org/10.1001/jamapediatrics.2025.4771
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared with Placebo in Children with Achondroplasia (ApproaCH), ClinicalTrials.gov ID NCT05598320, https://clinicaltrials.gov/study/NCT05598320
About Writer
Karthik Teja, Pharm.D.
He is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.